Author

P. Verachi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:mouse· 2 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. R. Migliaccio· 2 shared F. Gobbo· 2 shared F. Martelli· 2 shared A. C. Dueck· 1 shared A. Dunbar· 1 shared A. Karzai· 1 shared A. Krishnan· 1 shared A. Peli· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. R. Migliaccio

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

GATA1-defective immune-megakaryocytes as possible drivers of idiopathic pulmonary fibrosis

F. Gobbo, M. Zingariello, P. Verachi, M. Falchi, F. Arciprete, F. Martelli, A. Peli, M. Mazzarini, J. Vierstra, C. Mead-Harvey, A. C. Dueck, G. Sarli, S. Nava, G. Sgalla, L. Richeldi, A. R. Migliaccio

The paper identifies GATA1-defective immune-megakaryocytes in IPF patients and mice, showing their role in lung fibrosis through TGF-β1, CXCL1, and P-selectin mechanisms.

bioRxiv · Jun 20, 2023 · PreprintImmunology

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis

A. Dunbar, D. Kim, M. Lu, M. Farina, J. L. Yang, Y. Park, F. Gobbo, P. Verachi, F. Martelli, A. Karzai, W. Xiao, L. Xia, N. Elmansy, M. Kleppe, Z. Chen, , R. Hoffman

This study identifies CXCL8/CXCR2 signaling as a driver of bone marrow fibrosis in myelofibrosis and shows its therapeutic potential through genetic and pharmacologic inhibition.

bioRxiv · Dec 8, 2021Cancer Biology